HRP20020366B1 - Sodium-hydrogen exchanger type 1 inhibitor crystal - Google Patents

Sodium-hydrogen exchanger type 1 inhibitor crystal

Info

Publication number
HRP20020366B1
HRP20020366B1 HR20020366A HRP20020366A HRP20020366B1 HR P20020366 B1 HRP20020366 B1 HR P20020366B1 HR 20020366 A HR20020366 A HR 20020366A HR P20020366 A HRP20020366 A HR P20020366A HR P20020366 B1 HRP20020366 B1 HR P20020366B1
Authority
HR
Croatia
Prior art keywords
sodium
exchanger type
hydrogen exchanger
inhibitor crystal
inhibitor
Prior art date
Application number
HR20020366A
Other languages
English (en)
Inventor
Robinson Brostrom Lyle
Joseph Connolly Terrence
Jane Li Zheng
Lee Orrill Susan
Kiritkumar Shah Bharat
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HRP20020366A2 publication Critical patent/HRP20020366A2/hr
Publication of HRP20020366B1 publication Critical patent/HRP20020366B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20020366A 1999-10-29 2002-04-25 Sodium-hydrogen exchanger type 1 inhibitor crystal HRP20020366B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (2)

Publication Number Publication Date
HRP20020366A2 HRP20020366A2 (en) 2004-02-29
HRP20020366B1 true HRP20020366B1 (en) 2005-04-30

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020366A HRP20020366B1 (en) 1999-10-29 2002-04-25 Sodium-hydrogen exchanger type 1 inhibitor crystal

Country Status (44)

Country Link
EP (1) EP1224179B1 (tr)
JP (1) JP2003512455A (tr)
KR (1) KR100464526B1 (tr)
CN (2) CN1636991A (tr)
AP (1) AP2002002493A0 (tr)
AR (1) AR029402A1 (tr)
AT (1) ATE271047T1 (tr)
AU (1) AU778573B2 (tr)
BG (1) BG106729A (tr)
BR (1) BR0015275A (tr)
CA (1) CA2389020A1 (tr)
CO (1) CO5271714A1 (tr)
CZ (1) CZ20021332A3 (tr)
DE (1) DE60012208T2 (tr)
DK (1) DK1224179T3 (tr)
DZ (1) DZ3463A1 (tr)
EA (1) EA004937B1 (tr)
EE (1) EE200200227A (tr)
ES (1) ES2222923T3 (tr)
GE (1) GEP20043222B (tr)
GT (1) GT200000180A (tr)
HK (1) HK1048472B (tr)
HR (1) HRP20020366B1 (tr)
HU (1) HUP0204009A3 (tr)
IL (1) IL148581A0 (tr)
IS (1) IS6302A (tr)
MA (1) MA26840A1 (tr)
MX (1) MXPA02004358A (tr)
NO (1) NO20021821D0 (tr)
NZ (1) NZ517738A (tr)
OA (1) OA12080A (tr)
PA (1) PA8505501A1 (tr)
PE (1) PE20010764A1 (tr)
PL (1) PL354869A1 (tr)
PT (1) PT1224179E (tr)
SI (1) SI1224179T1 (tr)
SK (1) SK5312002A3 (tr)
SV (1) SV2002000209A (tr)
TN (1) TNSN00210A1 (tr)
TR (1) TR200201167T2 (tr)
UA (1) UA72002C2 (tr)
WO (1) WO2001030759A2 (tr)
YU (1) YU31502A (tr)
ZA (1) ZA200203295B (tr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
JP2004518686A (ja) * 2001-01-31 2004-06-24 ファイザー・プロダクツ・インク ナトリウム−水素交換輸送体１型阻害剤のエタノラート
EP1472242A1 (en) * 2002-01-30 2004-11-03 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
WO2003092694A1 (en) * 2002-05-02 2003-11-13 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100449600B1 (ko) * 1998-02-27 2004-09-21 화이자 프로덕츠 인크. 허혈 치료용 ｎ-[(치환된 5원 디아자 이불포화 고리)카르보닐] 구아니딘 유도체

Also Published As

Publication number Publication date
EA200200416A1 (ru) 2002-10-31
CN1636991A (zh) 2005-07-13
KR20020040918A (ko) 2002-05-30
BR0015275A (pt) 2002-07-16
DZ3463A1 (fr) 2001-05-03
NO20021821L (no) 2002-04-18
UA72002C2 (en) 2005-01-17
CZ20021332A3 (cs) 2002-10-16
EP1224179A2 (en) 2002-07-24
SK5312002A3 (en) 2003-01-09
BG106729A (bg) 2002-12-29
PA8505501A1 (es) 2003-09-05
AU7441500A (en) 2001-05-08
PL354869A1 (en) 2004-03-08
DE60012208T2 (de) 2005-07-21
NO20021821D0 (no) 2002-04-18
CO5271714A1 (es) 2003-04-30
AR029402A1 (es) 2003-06-25
OA12080A (en) 2003-08-25
SV2002000209A (es) 2002-07-16
ES2222923T3 (es) 2005-02-16
KR100464526B1 (ko) 2005-01-03
WO2001030759A3 (en) 2001-09-13
DE60012208D1 (de) 2004-08-19
WO2001030759A2 (en) 2001-05-03
HK1048472B (zh) 2005-09-16
HK1048472A1 (en) 2003-04-04
PT1224179E (pt) 2004-10-29
AP2002002493A0 (en) 2002-06-30
EP1224179B1 (en) 2004-07-14
CN1205205C (zh) 2005-06-08
DK1224179T3 (da) 2004-10-25
JP2003512455A (ja) 2003-04-02
HUP0204009A2 (hu) 2003-03-28
MA26840A1 (fr) 2004-12-20
NZ517738A (en) 2005-06-24
HUP0204009A3 (en) 2004-07-28
GEP20043222B (en) 2004-04-26
CN1384829A (zh) 2002-12-11
EE200200227A (et) 2003-06-16
SI1224179T1 (en) 2004-10-31
TR200201167T2 (tr) 2002-08-21
MXPA02004358A (es) 2002-11-07
IS6302A (is) 2002-03-15
ZA200203295B (en) 2003-06-25
CA2389020A1 (en) 2001-05-03
YU31502A (sh) 2004-12-31
EA004937B1 (ru) 2004-10-28
GT200000180A (es) 2002-04-11
AU778573B2 (en) 2004-12-09
PE20010764A1 (es) 2001-07-23
HRP20020366A2 (en) 2004-02-29
ATE271047T1 (de) 2004-07-15
IL148581A0 (en) 2002-09-12
TNSN00210A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
TW535893U (en) Heat exchanger
EP1164345A4 (en) Heat Exchanger
IL149097A0 (en) 4-carboxyamino-2-ethyl-1,2,3,4-thetrahydroquinoline crystal as cetp inhibitor
IL130438A0 (en) Heat exchanger
GB9919634D0 (en) Heat exchanger
SG78411A1 (en) Filter-heat exchanger
PL342763A1 (en) Matrix metaloprotease inhibitor
GB2343643B (en) Heat exchanger
EP1136783A4 (en) HEAT EXCHANGER
HRP20020366B1 (en) Sodium-hydrogen exchanger type 1 inhibitor crystal
DZ3310A1 (fr) Inhibiteurs de l'echangeur sodium-hydrogene de type 1
GB2389113B (en) B-secretase inhibitor
GB9928207D0 (en) Heat exchanger
IL139198A0 (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
EP1256771A4 (en) HEAT EXCHANGER
GB9824648D0 (en) Heat exchanger
GB9926629D0 (en) Heat exchangers
GB2338293B (en) Heat exchanger
GB9901538D0 (en) Heat exchanger
GB9803871D0 (en) Heat exchanger
EP1111322A4 (en) HEAT EXCHANGER
GB9911768D0 (en) Heat exchanger
GB9905367D0 (en) Heat exchanger
GB9930756D0 (en) Heat exchanger
GB9903868D0 (en) Heat exchanger

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20051010

Year of fee payment: 6

PBON Lapse due to non-payment of renewal fee

Effective date: 20061010